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Background: EGFR is important in maintaining metabolic homeostasis in healthy cells, but in tumors it activates
downstream signaling pathways, causing proliferation, angiogenesis, invasion and metastasis. Consequently, EGFR is
targeted in cancers using reversible, irreversible or antibody inhibitors. Unfortunately, tumors develop inhibitor
resistance by mutations or overexpressing EGFR, or its ligand, or activating secondary, EGFR-independent pathways.
Methods: Here we present a global metaanalysis comparing transcriptional profiles from matched pairs of EGFR
inhibitor-sensitive vs. -resistant cell lines, using 15 datasets comprising 274 microarrays. We also analyzed separately
pairs of cell lines derived using reversible, irreversible or antibody inhibitors.
Results: The metaanalysis identifies commonalities in cell lines resistant to EGFR inhibitors: in sensitive cell lines, the
ontological categories involving the ErbB receptors pathways, cell adhesion and lipid metabolism are overexpressed;
however, resistance to EGFR inhibitors is associated with overexpression of genes for ErbB receptors-independent
oncogenic pathways, regulation of cell motility, energy metabolism, immunity especially inflammatory cytokines
biosynthesis, cell cycle and responses to exogenous and endogenous stimuli. Specifically in Gefitinib-resistant cell
lines, the immunity-associated genes are overexpressed, whereas in Erlotinib-resistant ones so are the mitochondrial
genes and processes. Unexpectedly, lines selected using EGFR-targeting antibodies overexpress different gene ontologies
from ones selected using kinase inhibitors. Specifically, they have reduced expression of genes for proliferation,
chemotaxis, immunity and angiogenesis.
Conclusions: This metaanalysis suggests that ‘combination therapies’ can improve cancer treatment outcomes.
Potentially, use of mitochondrial blockers with Erlotinib, immunity blockers with Gefitinib, tyrosine kinase inhibitors with
antibody inhibitors, may have better chance of avoiding development of resistance.
Keywords: Development of resistance, Erlotinib, Gefitinib, Metabolic changes, Targeted therapyBackground
Cancer is principally caused by changes in three types of
genes i.e. oncogenes, tumor suppressor genes and DNA
stability genes; common environmental factors contribut-
ing to these changes could be smoking, oncogenic viruses,
occupational and environmental carcinogens and predis-
posing genetic polymorphisms [1,2]. Massive research ef-
forts are ongoing to find treatments for cancer, still an
unresolved problem and of course a heavy burden on* Correspondence: Miroslav.Blumenberg@nyumc.org
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unless otherwise stated.health care. Targeting specific pathways and modulating
the immune system are key strategies to control cancer
progression and increase effectiveness of treatment [3].
EGFR, important growth factor receptor implicated in
many cancers, is one of the targets for chemotherapy.
EGFR belongs to ErbB family of tyrosine kinase receptors
[4]. In tumors these receptors are activated by increased
expression or structural rearrangement of receptor gene,
mutation in ligand binding or tyrosine kinase domain or
by the production of autocrine and paracrine ligands. On
activation, EGFR dimerizes and triggers Ras-RAF-MEK-
ERK-MAPK, JAK-STAT and other signaling cascades
[4,5]. These pathways activate transcription factors,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cluding proliferation, carbohydrate utilization, protein
synthesis, angiogenesis, cell growth and cell survival [4,6].
In cancer cells, EGFR activation is important in maintain-
ing the metabolic homeostasis and stimulates prolifera-
tion, invasion, angiogenesis, survival, decreased apoptosis,
migration, differentiation and adhesion. Because of its
central signaling position, EGFR is targeted in number of
malignancies e.g. lung, colorectal, pancreatic, head and
neck cancers, glioblastomas etc. [7].
To treat malignancies, EGFR activity is targeted with
reversible, irreversible or antibody inhibitors and their
combinations. Reversible inhibitors, e.g., Gefitinib and
Erlotinib, compete for the intracellular ATP binding site
of the kinase; the irreversible inhibitors, e.g., PF299804
and WZ4002, block the ATP binding site by covalent
interaction with Cys773 in EGFR [8]. Antibody inhibi-
tors block the extracellular ligand binding domain of
EGFR thereby preventing ligand binding and receptor
dimerization. Different types of inhibitors generate differ-
ent transcriptional responses in EGFR-targeted cells [9].
Unfortunately, after a period, tumors inexorably de-
velop resistance to inhibitors by e.g., overexpression of
EGFR ligand, activating mutations in the tyrosine kinase
or the ligand-binding domain, or by mutations in down-
stream or parallel signaling pathways, e.g., Axl or IGFIR
[10-14]. Multiple studies focused on defining the sec-
ondary mutations that cause resistance to EGFR inhibi-
tors [13-15]. However, much less attention has been
paid to the transcriptional and metabolic changes that
distinguish the resistant cells from the sensitive ones
[12]. Therefore, we decided to explore the fundamental
functional changes that distinguish the resistant cells
from the sensitive ones, using transcriptional profiling.
To cast a wide net, we used metaanalysis approach to
find the differential gene expression between matched
pairs of cell lines sensitive and resistant to EGFR inhibi-
tors. Here we included eight studies with 15 distinct
datasets directly comparing the transcriptional profiles
in EGFR inhibitor-sensitive vs. resistant cell lines. The
cell lines included non-small cell lung cancer, head and
neck cancer, and epidermoid carcinoma cell lines. The
inhibitors included both reversible and irreversible kin-
ase inhibitors, as well as antibodies.
We found that in EGFR inhibitor-sensitive cell lines
characteristically overexpressed gene ontologies are ad-
hesion, negative regulation of cell proliferation, lipid me-
tabolism and oncogenic processes involving ErbB
receptors. But when cells become resistant, ontological
categories associated with energy metabolism, immunity
involving overexpressing inflammatory cytokines, re-
sponses to external and internal stimuli, proliferation
and ErbB-independent oncogenic pathways are overex-
pressed. The specific resistance to Gefitinib apparentlydevelops by overexpressing immunomodulatory genes;
resistance to Erlotinib by energy producing mitochon-
drial pathways; resistance to irreversible inhibitors by
overexpressing EGFR ligands, whereas resistance to anti-
body inhibitors develops differently from the resistance
to tyrosine kinase inhibitors.
Methods
Downloading the data files
The overall flowchart of our methodology is graphically
represented in Additional file 1: Figure S1.
Different microarray platforms used for transcriptional
profiling produced different, characteristic data files,
which were worked up separately and then synchro-
nized. The CEL or TXT files deposited in these studies
were first downloaded and unzipped. For each study,
data obtained from sensitive and resistant cell lines were
saved in different columns of excel spread sheets. Data-
sets obtained from Affymetrix studies were combined
and analyzed using RMAExpress for quality control
[16,17]. For non-Affymetrix studies, where we could not
run RMAExpress quality control, we downloaded already
normalized, _RAW.tar files and used these without further
modifications, as submitted by the original authors.
Grouping studies for analysis using RankProd software
RankProd package analyses gene expression microarray
data specifically to identify differentially expressed genes.
RankProd uses non-parametric rank product method to
detect genes that are consistently found among the most
strongly upregulated ones and the most strongly downreg-
ulated ones in a number of replicate experiments, compar-
ing two different condition [18]. We have combined into a
single spreadsheet microarray data for sensitive and resist-
ant cell lines with 20552 common genes in all datasets
using data-loader [17]. Five datasets comprising 214 micro-
arrays and 28235 genes for Gefitinib-sensitive and resistant
cell lines were combined into a single excel spreadsheet
and analyzed using RankProd. Differentially expressed
genes in each of the class were recorded. Microarray data
for the seven datasets comprising forty Erlotinib-sensitive
and resistant microarrays, having 32062 common genes
were combined for analysis using RankProd software [17].
We have pooled and compared the microarray data for
EGFR irreversible inhibitors from two datasets, fourteen
microarrays and 21631 common genes. For studying
EGFR antibody inhibitors responses we found a single
study with 3 microarrays from Cetuximab-sensitive and
3 from resistant cell lines, with 48607 genes.
We used the RankProd Software to find out the genes
differentially expressed in EGFR inhibitor-sensitive and re-
sistant cell lines with p-values better than 10−4. For each
analysis we derived two tables, one representing the onto-
logical categories over expressed in sensitive cell lines and
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ant cell lines [18]. The results of the RankProd analysis are
presented in Additional file 2: Figure S2.
DAVID analysis
We used online Database for Annotation, Visualization
and Integrated Discovery (DAVID) software as described
before [17,19]. We also generated clusters, which reduced
overlaps and redundancies in regulated ontological cat-
egories, for Erlotinib-, irreversible inhibitor- and
Cetuximab-sensitive and resistant cell lines. These are
provided in Additional files 3,4,5,6,7, and 8.
Results
Datasets characterization
Inhibitors have been studied principally to find out their
mechanism of action in different cancer types. We here
aim to study the differential gene expression in EGFR
inhibitor-sensitive vs. resistant cancer cell lines. We
searched GEO Datasets using key term “EGFR Resist-
ance” and, limiting our choices to human cell lines, se-
lected studies that directly compare transcriptional
profiles of matched EGFR inhibitor-sensitive vs. resistant
datasets (Table 1). We found 8 appropriate studies com-
prising 15 datasets and 274 microarrays. In seven data-
sets EGFR inhibitor-sensitive vs. resistant cell lines were
compared without any other treatment. In one study
comprising four datasets (GSE38310), two different typesTable 1 EGFR inhibitors-sensitive versus resistant cell lines da
Sr. No Acc. No. Platform Set S+R S cell lines R
1 GSE34228 Agilent-014850 1 26+26 PC9 PC
2 26+26 PC9 PC
3 26+26 PC9 PC
4 26+26 PC9 PC
2 GSE10696 Affy HG_ U133_Plus_2.0 1 3+3 A431 A4
3 GSE38310 Illumina HumanHT-12
V3.0
1 3+3 HCC827 T1
2 3+3 HCC827 T1
3 3+3 HCC827 ER
4 3+3 HCC827 ER
4 GSE40130 Illumina HumanWG-6 v3.0 1 2+3 HN5 FA
Illumina HumanHT-12
V4.0
2 2+3 HN5 FA
5 GSE49135 Illumina HumanHT-12
V4.0
1 3+3 HN5 HN
6 GSE37699 Affy_HG_U133A_2 1 3+3 NSCLC NC
7 GSE38404 Affy_HG_U133A_2 1 2+6 NSCLC PF
PF
8 GSE21483 Affy HG_ U133_Plus_2.0 1 3+3 SCC1 1C
Total 15 274of Erlotinib-resistant cell lines were originated from
Erlotinib-sensitive cell lines and then treated either with
DMSO or Erlotinib. We compared DMSO-treated sensi-
tive cell lines with DMSO-treated resistant cell lines and
Erlotinib-treated sensitive cell lines with Erlotinib-
treated resistant cell lines. In a Gefitinib study compris-
ing three datasets [10], sensitive and resistant cell lines
were treated with Gefitinib and EGF separately or in
combination (GSE34228). In one study Erlotinib-sensitive
and resistant cell lines were treated with miR-7
(GSE40130). In another study, GSE38404, resistant cell
lines were produced by exposing the sensitive cell lines to
inhibitor for different time periods. We have combined
data from all the resistant cell lines for metaanalysis.
Illumina microarrays were used in majority of datasets,
comprising 3 studies and 7 datasets. In four studies, com-
paring four datasets Affymetrix microarrays were used.
Agilent microarrays were used in one study comparing
four datasets. Different studies used different types of cell
lines for example Non-Small Cell Lung Cancer, Head and
Neck Cancer, A431 and Skin cancer cell lines; therefore,
we have also individually compared datasets from individ-
ual studies (data not shown).
Information about the type of sensitive and resistant
cells, pretreatment and type of EGFR inhibitor, labeling
accession number, platform, number of datasets, number
of sensitive and resistant microarray chips in each data-
set is summarized in Table 1.tasets used in metaanalysis of microarrays
Cell lines Cell Type Pretreatment Inhibitor
9GR Non-Small Cell Lung Cancer No Gefitinib
9GR Non-Small Cell Lung Cancer EGF Gefitinib
9GR Non-Small Cell Lung Cancer IRS Gefitinib
9GR Non-Small Cell Lung Cancer EGF+IRS Gefitinib
31GR A431 cancer cell line No Gefitinib
5-2 Non-Small Cell Lung Cancer DMSO Erlotinib
5-3 Non-Small Cell Lung Cancer Erlotinib Erlotinib
-3 Non-Small Cell Lung Cancer DMSO Erlotinib
-3 Non-Small Cell Lung Cancer Erlotinib Erlotinib
DU Head and Neck cancer cell
lines
No Erlotinib
DU Head and Neck cancer cell
lines
miR-7 Erlotinib
5ER Head and Neck cancer cell
lines
No Erlotinib
l-H1975 Non-Small Cell Lung Cancer No WZ4002
R31,
R32
Non-Small Cell Lung Cancer No PF299804
c8 Skin cancer cell line No Cetuximab
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proaches; 1) datasets comparing all EGFR inhibitor-
sensitive vs. resistant cell lines; 2) Gefitinib- and 3)
Erlotinib-sensitive vs. resistant cell lines; 4) irreversible
inhibitor-sensitive vs. resistant cell lines; 5) Cetuximab-
sensitive vs. resistant cell lines [11]. We used RankProd
software to select differentially expressed genes in these
individual groups i.e. sensitive vs. resistant, with results
graphically presented in (Additional file 2: Figure S2).
Ontological categories overrepresented in lists of dif-
ferentially expressed genes were identified using DAVID
[19]; complete lists are given in Additional files 3, 4, 5, 6
and 7. To condense redundancies, we have also identi-
fied clusters for differentially expressed ontological cat-
egories in the sensitive vs. Erlotinib-, Irreversible- and
Cetuximab-resistant groups (see below).Global comparison of all EGFR inhibitors-sensitive vs. resistant
cell lines
We have compared overexpressed ontological categories
in all sensitive vs. resistant cell lines. Table 2a contains the
10 categories with the best p-values; in Table 2b, we se-
lected the characteristically different categories between
sensitive and resistant cells with p-values better than 10−4.
In Table 2a, we find that in the sensitive cell lines the
genes related to systems involved in transport of mate-
rials across the membranes are overexpressed, whereas
in the resistant cell lines the genes related to the metab-
olism and macromolecule biosynthesis, especially of pro-
teins, are overexpressed. Although we have found genes
associated with regulation of the protein translation in
both groups, this category is more significant in the re-
sistant cell lines. Both EGFR inhibitor-sensitive and re-
sistant cell lines overexpress cell proliferation genes,
however the sensitive cell lines tend to overexpress
apoptosis and cancer-related genes as well. Interestingly,
the resistant cell lines seem significantly more responsive
to various endogenous and exogenous stimuli than the
sensitive ones.
Oncogenesis-related genes and pathways are up-
regulated in both sensitive and resistant cell lines. As re-
ported in previous studies, in sensitive cell lines tumor
growth seems dependent on the oncogene activation
through ErbB receptor kinases [15]. In contrast, in resist-
ant cell lines often the Ras pathway is activated independ-
ently of receptors (Table 2b). We note that while Ras is
considered a downstream target of EGFR signaling in
noncancerous cells [20], the EGFR- and Ras-associated
genes comprise widely different groups (Table 2c).
Interestingly, we have observed that in the sensitive cell
lines lipids are preferentially metabolized as the source of
energy. But as cells become resistant, both carbohydrates
and lipids are metabolized to provide energy. In addition,resistant cell lines are inducing the expression of energy
generating genes, including the oxidoreductases. This ob-
servation suggests that energy production is an important
matter for development of resistant cell lines.
Genes involved in responses to various extracellular
and intracellular stimuli, for example steroid hormone,
hydrogen peroxide and stress, are over expressed signifi-
cantly in the resistant cell lines compared to sensitive
ones. These responses may be related either to cells’ pro-
tection from toxins or overall cell survival, as stress and
hydrogen peroxide responses prepare the cell for a toxic
environment and steroids stimulate proliferation in cer-
tain cancers [21,22]. Those cancer cells that increase ex-
pression of genes responsive to these stimuli tend to
adapt and survive [23].
We have also observed that certain processes related to
immunity are overexpressed in the sensitive as well as in
resistant cell lines, but we found that ontological categor-
ies for these processes have significantly better p-values in
the resistant ones. Further, detailed study of the genes in-
volved in immunity revealed that the innate immunity in-
volving the complement component system is active in
sensitive cells. In contrast, the resistant cells utilize both
innate and adaptive immune systems, especially involving
the cytokines and chemokines (Table 2d).
In EGFR inhibitor-sensitive cell lines, cell death and
proliferation are relatively suppressed. But in resistant
cell lines proliferation is relatively increased, while differ-
entiation is decreased, thus favoring cancer cells growth
and persistence. Another major distinction is that sensi-
tive cell lines strongly express adhesion-related genes,
whereas in resistant cells the genes related to cell move-
ment are overexpressed. This suggests that the resistant
cells have increased tendency to metastasize, perhaps via
EMT [13,24].
Comparison of Erlotinib-sensitive vs. resistant cell lines
Surprisingly, protein biosynthesis was the only onto-
logical category in the top ten differentially expressed
ones in Erlotinib-sensitive cell lines (Table 3a). In the re-
sistant cells, we have also found mitochondria, immunity
and cytoskeleton genes in the top ten ontological cat-
egories. In Erlotinib-sensitive cell lines, carbohydrate
and protein metabolism genes are overexpressed with
very good p-values, 10−21 (Table 3b). These lines seem
to utilize the maximum of their energy reservoirs from
glucose and protein molecules. Conversely, in the
Erlotinib-resistant cell lines, glycolysis and gluconeogene-
sis are suppressed and, importantly, genes related to mito-
chondria and mitochondrial processes are remarkably
boosted. These results suggest that increased production
of energy to support cellular metabolic processes and sur-
vival are very important in the development of Erlotinib
resistance. From these observations we suggest that
Table 2 Global comparison of the ontological categories differentially expressed in EGFR inhibitors-sensitive vs.
resistant cell lines
All studies: Overexpressed in sensitive cells Overexpressed in resistant cells
Term p-value Term p-value
Table 2a
O Pathways in cancer 4.9E-15 T positive regulation of biosynthetic process 3.6E-17
MM plasma membrane part 7.7E-12 T positive regulation of cellular biosynthetic process 5.2E-17
CC regulation of cell proliferation 1.3E-10 T positive regulation of macromolecule Metabolic process 2.3E-16
MM endomembrane system 1.4E-10 R response to endogenous stimulus 8.9E-16
MM cell fraction 2.1E-09 T positive regulation of nitrogen compound Metabolic
process
1.6E-15
A regulation of cell death 2.2E-09 T positive regulation of macromolecule biosynthetic
process
9.3E-15
A regulation of programmed cell death 2.6E-09 CC regulation of cell proliferation 4.9E-14
Mt positive regulation of macromolecule Metabolic
process
2.6E-09 R response to hormone stimulus 6.9E-14
CC cell proliferation 5.7E-09 R response to organic substance 9.6E-14
T protein complex biogenesis 7.0E-09 CC positive regulation of nucleobase, nucleoside,
nucleotide and nucleic acid Metabolic process
1.2E-13
Table 2b
A negative regulation of cell death 1.4E-07 A regulation of apoptosis 3.3E-10
AD cell migration 5.0E-08 A negative regulation of apoptosis 4.1E-10
AD cell adhesion 2.3E-07 A anti-apoptosis 8.1E-08
AD localization of cell 1.2E-06 CC cell cycle 8.2E-06
AD cell projection 3.2E-06 CC regulation of cell size 3.4E-05
AD Focal adhesion 4.3E-05 CY cytoskeletal protein binding 3.2E-06
CC negative regulation of cell proliferation 9.0E-05 CY actin cytoskeleton 1.0E-04
CC regulation of DNA Metabolic process 1.5E-04 DF negative regulation of cell differentiation 6.1E-06
CC mitotic cell cycle 5.9E-04 E regulation of oxidoreductase activity 5.1E-05
CC regulation of cell size 6.4E-04 E positive regulation of oxidoreductase activity 4.2E-04
IM response to wounding 4.4E-05 IM immune system development 1.8E-09
IM immune system development 6.2E-04 IM response to wounding 2.4E-08
IM T cell activation 6.8E-04 IM regulation of cytokine production 1.1E-07
IM humoral immune response 8.4E-04 IM positive regulation of immune system process 4.3E-06
M_c oligosaccharide Metabolic process 7.0E-04 IM positive regulation of cell activation 2.6E-05
M_l regulation of lipid Metabolic process 6.8E-06 IM inflammatory response 2.8E-05
M_l phosphoinositide Metabolic process 7.3E-05 IM wound healing 1.6E-04
M_l positive regulation of lipid Metabolic process 1.0E-04 IM immune response 1.8E-04
M_l lipid biosynthetic process 1.1E-04 IM defense response 4.5E-04
M_l phospholipid Metabolic process 2.3E-04 IM regulation of production of molecular mediator
of immune response
9.1E-04
M_l cellular lipid catabolic process 4.2E-04 M_c monosaccharide Metabolic process 4.3E-06
M_l glycerolipid Metabolic process 5.4E-04 M_c hexose Metabolic process 1.2E-05
M_l glycerophospholipid Metabolic process 7.0E-04 M_c glucose Metabolic process 5.8E-05
M_l lipoprotein particle clearance 9.2E-04 M_c regulation of cellular ketone Metabolic process 2.0E-04
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Table 2 Global comparison of the ontological categories differentially expressed in EGFR inhibitors-sensitive vs.
resistant cell lines (Continued)
O Oncogenesis 3.4E-05 M_l regulation of lipid Metabolic process 2.6E-07
O ErbB signaling pathway 4.2E-04 M_l regulation of lipid biosynthetic process 1.1E-04
O Wnt signaling pathway 7.7E-04 M_l regulation of fatty acid Metabolic process 4.2E-04
M_l positive regulation of lipid Metabolic process 4.9E-04
Legend: MO regulation of cell motion 2.8E-12
A Apoptosis O Pathways in cancer 2.8E-10
AD Adhesion O regulation of DNA Metabolic process 1.2E-04
CC Cell cycle O Ras protein signal transduction 2.1E-04
CY Cytoskeleton O Oncogenesis 4.0E-04
DF Differentiation R response to steroid hormone stimulus 6.2E-12
E Energy R response to insulin stimulus 1.5E-07
Mt Metabolism R response to vitamin 1.2E-06
IM Immunity R response to lipopolysaccharide 1.8E-06
M_c Metabolism-carbohydrates R response to glucocorticoid stimulus 2.6E-06
M_l Metabolism-lipids R response to hydrogen peroxide 1.4E-05
MM Membrane R cellular response to stress 3.1E-05
MO Motility V regulation of angiogenesis 4.6E-06
O Oncogenesis V myeloid leukocyte activation 4.4E-05





ErbB Signalling pathway Ras protein signal transduction
BCL2-associated agonist of cell death v-ral oncogene homolog A
mitogen-activated protein kinase 9 FERM, RhoGEF and pleckstrin domain
phosphoinositide-3-kinase beta nischarin
glycogen synthase kinase 3 beta IGF1 (somatomedin C)
c-abl oncogene 1 Rho GTPase activating protein 6
v-crk sarcoma virus CT10 X-associated ankyrin-containing protein
mitogen-activated protein kinase 8 ras homolog gene family, member A
ribosomal protein S6 kinase myosin IXB
mitogen-activated protein kinase 10 mitogen-activated protein kinase 1
phosphoinositide-3-kinase alpha GRB2-related adaptor protein 2
phospholipase C, gamma 1 Rho GTPase activating protein 5
CDK inhibitor 1A (p21, Cip1) soc-2 suppressor of clear homolog
epiregulin mitogen-activated protein kinase 14
v-myc oncogene homolog ropporin, rhophilin associated protein 1B
phosphoinositide-3-kinase subunit 5 r-ras oncogene homolog
v-erb-b2 oncogene homolog 2 CDC42 effector protein
v-aktoncogene homolog 1 fibroblast growth factor 2 (basic)
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Table 2 Global comparison of the ontological categories differentially expressed in EGFR inhibitors-sensitive vs.
resistant cell lines (Continued)
calcium/calmodulin-dep. protein kinase II G protein alpha 12
protein kinase C, alpha parathyroid hormone
neuregulin 1 GRB2-related adaptor protein
NCK adaptor protein 1 muscle RAS oncogene homolog
PTK2 protein tyrosine kinase 2 WAS protein family, member 2
phosphoinositide-3-kinase delta SHC transforming protein 1
betacellulin MAPKAP 2
ribosomal protein S6 kinase 2 Rho guanine nucleotide exchange factor 3
jun oncogene ATP-binding cassette, member 1
p21 (Cdc42/Rac)-activated kinase 2 cofilin 1 (non-muscle)
translation initiation factor 4E binding CDC42 effector protein 4
phospholipase C, gamma 2 neurofibromin 1
neurotrophic tyrosine kinase, type 1
ral GDF stimulator-like 2




complement component 2 complement component 1, q A chain
complement component 3a receptor 1 complement component 1, q B chain
complement component 7 complement factor H
complement component 8, alpha






chemokine (C-C motif) ligand 2 chemokine (C-C motif) ligand 13
chemokine (C-C motif) ligand 22 chemokine (C-C motif) ligand 19
chemokine (C-C motif) ligand 23 chemokine (C-C motif) ligand 2
chemokine (C-C motif) ligand 24 chemokine (C-C motif) ligand 20
chemokine (C-C motif) receptor 5 chemokine (C-C motif) ligand 8
chemokine (C-C motif) receptor 5
chemokine (C-X-C motif) ligand 1
chemokine (C-X-C motif) ligand 13
chemokine (C-X-C motif) ligand 6
Interleukins
interleukin 1, alpha interleukin 1 family, member 6
interleukin 10 interleukin 1, alpha
interleukin 2 receptor, alpha interleukin 1, beta
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Table 2 Global comparison of the ontological categories differentially expressed in EGFR inhibitors-sensitive vs.
resistant cell lines (Continued)
interleukin 6 (interferon, beta 2) interleukin 10




interleukin 6 (interferon, beta 2)
interleukin 9
The data represent the ontological and functional categories identified as overrepresented in the lists of differentially expressed genes, when compared to all genes in
the human genome. The lists are provided by the DAVID analysis program [17,19]. a) Top ten categories with best p-values. b) Selected categories with p-value better
than 10-4. For complete list of categories with p-values better than 10-4 see Additional file 3; the selected categories represent our choices as the ones that illustrate the
best differences between resistant and sensitive cell lines. c) Genes expressed in ErbB signaling pathway and Ras protein signal transduction ontologies of sensitive and
resistant cell lines respectively. d) Genes expressed in immune system development of sensitive versus resistant cell lines.
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cells survival in the presence of EGFR inhibitors.Comparison of Gefitinib-sensitive vs. resistant cell lines
In the Table 4a, we show that the cancer-related genes and
pathways are preferentially activated in the sensitive cell
lines. But in the cells resistant to Gefitinib, the ontological
categories related to macromolecule biosynthesis, specific-
ally of proteins, are most significantly overexpressed.
Apparently, the sensitive cell lines have higher tendency for
attachment, as the adhesion related genes are upregulated
in these, whereas the resistant cell lines are significantly
more responsive to endogenous and exogenous stimuli. In
the sensitive cell lines ontological categories related to cell
cycle, metabolism of proteins and signaling are also up
regulated, but the p-values are not as significant as in the
resistant cell lines. Tumor related pathways and cell
cycle-related genes are also relatively upregulated in
resistant cell lines.
Interestingly, we have not found any ontological category
related to immune system development overexpressed in
the sensitive cell lines. In contrast, in the resistant cell lines
immunity systems, specifically biosynthesis of cytokines
genes, are boosted (Table 4b). This suggests that Gefitinib-
resistant cell lines use cytokines of the immune systems to
develop resistance against Gefitinib and thus maintain
tumor cells growth and progression [25].
In resistant cells the ontological categories related to
responses to various stimuli and angiogenesis were ro-
bustly and consistently overexpressed. We have also
found increased expression of genes responsive to react-
ive oxygen species, which ultimately tends to activate
apoptosis and immunity pathways in these cells. Expres-
sion of genes related to hypoxia has also been seen in
the resistant cell lines, which may increase their drug re-
sistance and ultimately their growth rate [26].
Both in Gefitinib-sensitive and in resistant cell lines
proliferation and apoptosis are regulated. However, inthe resistant cell lines, the cell death processes are nega-
tively regulated and the cell division is enhanced, sug-
gesting that resistant cell lines have higher propensity to
survive. Meanwhile, responses to various endogenous
and exogenous stimuli are enhanced, maybe to cope
with stresses from environment. In addition, immunity
genes and cytokine biosynthesis are upregulated to help
cancer cells to survive and grow.
Interestingly, we have observed that lipid metabolism
genes are prominent in the sensitive cell lines, whereas
oxidoreductases, as well as both glucose and lipid metabol-
ism, i.e. genes related to production of energy, are more
prominent in the resistant cell lines. Energy requirements
for the tumor cells are met preferentially by formation of
new blood vessels but also by glucose and lipid metabolism.Comparison of sensitive vs. resistant cell lines obtained
using irreversible EGFR inhibitors
We have combined the microarray data from the cell
lines selected as resistant to irreversible EGFR inhibitors
WZ4002 and PF299804. Unexpectedly, in the top ten
categories from the sensitive cell lines, genes related to
membrane systems are found (Table 5a). In contrast, the
extracellular region-related ontological categories are
upregulated in the resistant cell lines. Cell cycle and lipid
metabolism categories are relatively upregulated in the
sensitive cell lines, similar to what was observed in re-
versible EGFR inhibitors-sensitive cell lines (Table 4b).
Ontological categories related to cell division were found
in both groups, however, in the resistant cell lines, cell
division is positively regulated with better p-value than
in sensitive cell lines. Importantly, the immunity genes
are relatively overexpressed in resistant cell lines, re-
inforcing our observation that cytokine overexpression is
one of the survival strategies gained by resistant cell
lines (Table 5b).
Surprisingly, we found increased expression of EGFR li-
gands in cells selected using irreversible inhibitors
Table 3 Comparison of ontological categories differentially expressed in Erlotinib-sensitive vs. resistant cell lines, using
DAVID program
Erlotinib: Overexpressed in sensitive cells Overexpressed in resistant cells
Term p_value Term p_value
Table 3a
T translation 5.6E-62 cytosol 3.0E-20
T translational elongation 6.3E-45 T translational elongation 3.1E-18
T structural constituent of ribosome 1.0E-43 T structural constituent of ribosome 3.4E-18
cytosol 3.7E-41 T ribosomal subunit 3.5E-17
T ribosome 4.5E-41 T cytosolic ribosome 2.4E-16
T 3' -UTR-mediated translational regulation 3.8E-40 E mitochondrion 1.5E-15
T ribonucleoprotein complex 5.0E-40 T Ribosome 2.6E-14
T Ribosome 4.6E-37 T ribosome 2.6E-14
T ribosomal subunit 9.9E-36 IM Influenza Infection 4.2E-14
T Protein biosynthesis 2.0E-33 CY intracellular non-membrane-bounded organelle 8.2E-13
Table 3b
CC Cell cycle 1.8E-04 CC mitotic cell cycle 3.2E-08
E mitochondrion 2.4E-10 CC M phase of mitotic cell cycle 9.1E-06
E intramolecular oxidoreductase activity 4.4E-04 CY actin cytoskeleton 5.3E-06
M_c glycolysis 2.1E-07 E mitochondrial inner membrane 7.1E-12
M_c Metabolism of carbohydrates 3.3E-06 E mitochondrial envelope 7.2E-12
M_c carbohydrate catabolic process 7.5E-05 E oxidative phosphorylation 1.5E-10
M_c Glycolysis / Gluconeogenesis 1.7E-04 E hydrogen ion transmembrane transporter activity 1.8E-10
M_c glucose metabolic process 6.4E-04 E generation of precursor metabolites and energy 3.4E-10
T Metabolism of proteins 5.4E-29 E Oxidoreductase 6.6E-10
T ribosome biogenesis 6.6E-21 E Dehydrogenase 3.9E-09
T ncRNA metabolic process 4.7E-19 E Integration of energy metabolism 1.6E-06
T mitochondrial ribosome 4.0E-05 E electron transport chain 1.8E-05
E mitochondrial lumen 1.9E-04
E mitochondrial matrix 1.9E-04
E NADH dehydrogenase (ubiquinone) activity 2.3E-04
E mitochondrial ATP synthesis coupled electron transport 2.8E-04
T Metabolism of proteins 2.7E-09
T Protein biosynthesis 1.6E-07
T Gene Expression 1.5E-06
a) Top ten categories with best p-values. b) Selected categories with p-value better than 10-4 (see Additional file 4).
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EGFR-mediated signaling cascades. This differs from ob-
servations in cell lines selected for resistance to reversible
inhibitors, which use alternative pathways for oncogenes
activation (Tables 2b and 3b).
Comparison of Cetuximab-sensitive vs. resistant cell lines
For the analysis of cells selected as resistant to antibody
inhibitor Cetuximab, we could find only a single study
including six microarrays [27], which means that the
statistical robustness of the results is reduced. Interest-
ingly, we found that the differential gene expression inCetuximab-sensitive and resistant cell lines is quite un-
like the differential gene expression seen in the cell lines
obtained using tyrosine kinase inhibitors. This agrees
well with our previous study documenting that the tran-
scriptional responses to EGFR antibody inhibitors are dif-
ferent from those to kinase inhibitors [9]. In sensitive cell
lines, ontological categories related to immunity, cell pro-
liferation, cell migration and response to external stimulus
are overexpressed (Table 6a). In contrast, in the resistant
cell lines epithelium development- and differentiation-
associated gene ontologies are frequently and significantly
overexpressed. Intriguing, the ontological category for
Table 4 Comparison of ontological categories differentially expressed in Gefitinib-sensitive vs. resistant cell lines
Gefitinib: Overexpressed in sensitive cells Overexpressed in resistant cells
Term p_value Term p_value
Table 4a
O Pathways in cancer 6.8E-14 T positive regulation of biosynthetic process 1.7E-11
O Pancreatic cancer 1.2E-07 T positive regulation of macromolecule metabolic process 3.1E-11
T protein complex assembly 3.7E-06 T positive regulation of cellular biosynthetic process 3.5E-11
T protein complex biogenesis 3.7E-06 T positive regulation of nitrogen compound metabolic process 1.6E-10
CC regulation of cell proliferation 3.9E-06 T positive regulation of macromolecule biosynthetic process 4.4E-10
O Bladder cancer 7.8E-06 R response to endogenous stimulus 5.1E-10
S regulation of protein kinase cascade 8.7E-06 CC positive regulation of nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
3.6E-09
AD cell adhesion 9.0E-06 R response to hormone stimulus 8.1E-09
AD biological adhesion 9.8E-06 O Pathways in cancer 1.0E-08
T positive regulation of macromolecule metabolic
process
1.0E-05 T positive regulation of transcription 1.5E-08
Table 4b
A regulation of cell death 3.6E-05 A negative regulation of programmed cell death 1.0E-06
A negative regulation of cell death 4.4E-05 CC regulation of cell proliferation 3.5E-08
A regulation of apoptosis 7.9E-05 CC positive regulation of cell proliferation 1.9E-06
CC cell proliferation 1.6E-05 CC cell cycle 2.7E-04
M_l regulation of lipid metabolic process 3.1E-05 CY cytoskeleton organization 5.3E-06
M_l positive regulation of lipid metabolic process 3.4E-04 CY cell morphogenesis 2.0E-04
O ErbB signaling pathway 5.2E-04 E regulation of oxidoreductase activity 4.9E-04
HY response to hypoxia 8.7E-06
HY response to reactive oxygen species 2.4E-04
HY response to hydrogen peroxide 6.3E-04
IM immune system development 4.1E-07
IM regulation of cytokine production 9.2E-07
IM regulation of cytokine biosynthetic process 2.8E-06
IM response to wounding 7.3E-05
IM positive regulation of cytokine biosynthetic process 1.1E-04
IM Signaling in Immune system 1.3E-04
M_c glucose metabolic process 5.1E-04
M_l regulation of lipid metabolic process 2.9E-04
R response to steroid hormone stimulus 4.5E-08
R response to nutrient levels 3.6E-07
R response to extracellular stimulus 6.8E-07
R response to drug 2.5E-06
R response to nutrient 3.7E-05
R response to vitamin 3.7E-05
R response to corticosteroid stimulus 4.3E-05
R response to glucocorticoid stimulus 9.1E-05
R response to lipopolysaccharide 1.7E-04
R response to abiotic stimulus 3.4E-04
R negative regulation of response to external stimulus 6.8E-04
V hemopoiesis 1.2E-07
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(Continued)
V leukocyte differentiation 9.4E-06
V blood circulation 4.9E-05
V circulatory system process 4.9E-05
V lymphocyte differentiation 7.4E-05
V regulation of angiogenesis 1.1E-04
V blood vessel development 1.2E-04
V vasculature development 1.8E-04
a) Top ten categories with best p-values. b) Selected categories with p-value better than 10-4 (see Additional file 5).
Table 5 Comparison of ontological categories differentially expressed in irreversible inhibitor-sensitive vs. resistant cell
lines
Irreversible: Overexpression in sensitive cells Overexpression in resistant cells
Term p_value Term p_value
Table 5a
MM endomembrane system 3.8E-09 EC extracellular region 1.6E-08
MM Golgi apparatus 2.4E-07 ectoderm development 3.3E-07
MM cell fraction 1.0E-05 IM response to wounding 4.3E-07
CC cell division 2.1E-05 EC extracellular region part 1.3E-06
MM organelle membrane 3.1E-05 EC extracellular space 2.4E-06
MM nuclear envelope-endoplasmic reticulum network 5.9E-05 epidermis development 8.4E-06
R response to organic substance 8.1E-05 CC regulation of cell proliferation 1.1E-05
MM endoplasmic reticulum membrane 1.0E-04 CC regulation of smooth muscle cell proliferation 6.5E-05
CC Mitosis 1.1E-04 IM wound healing 7.3E-05
MM 1p22.1 1.5E-04 CC positive regulation of smooth muscle cell proliferation 1.9E-04
Table 5b
CC cell cycle 3.1E-04 IM defense response 5.9E-04
M_l steroid metabolic process 4.3E-04 IM inflammatory response 9.2E-04
O epidermal growth factor receptor binding 2.5E-04
O ErbB signaling pathway 4.2E-04
Genes overexpressed in resistant cells
Table 5c
EGFR Binding ligands ErbB sig pathway
amphiregulin; amphiregulin B Cas-Br-M ecotropic retroviral transforming sequence c
epidermal growth factor receptor amphiregulin; amphiregulin B
Epiregulin epidermal growth factor receptor
heparin-binding EGF-like growth factor epiregulin
heparin-binding EGF-like growth factor
transforming growth factor, alpha
v-erb-b2 oncogene homolog 3
a) Top ten categories with best p-values. b) Selected categories with p-value better than 10-4 (see Additional file 6). c) Genes expressed in EGFR binding and ErbB
signaling pathway ontologies in resistant cell lines.
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well, although it had relatively less significant p-value.
In Table 6b, the overregulated processes in Cetuximab-
sensitive cell line comprise immunity responses, signal trans-
duction involving JAK-STAT pathway and angiogenesis. In
contrast, in the resistant cell line genes for cell cycle, cell
structure and reduction of transcription are increased.Clustering of ontological categories in sensitive vs.
resistant cell lines
The charts comparing overexpressed ontological categories,
although very informative, contain many redundant and
overlapping ontological categories (Tables 2,3,4,5 and 6).
To get around this problem we have clustered the onto-
logical categories using DAVID software. Cluster outputs
for Erlotinib-, irreversible inhibitor and Cetuximab-
sensitive versus resistant cell lines are presented in
Additional file 8.
In Erlotinib-sensitive cell lines, transcription, transla-
tion and protein transport processes, marked as ‘T’
in Additional file 8a, are statistically more significant.
In contrast, we found mitochondria-related genes,
designated as ‘E’ for ‘energy’, the most frequent onto-
logical category in resistant cell lines. Ontologies related
to apoptosis, ‘A’, are the second most upregulated cat-
egory in sensitive cells. In resistant cell lines genes re-
lated to cell cycle, ‘CC’, and cytoskeleton, ‘CY’, are the
most expressed categories after energy production. In
sensitive cell lines apparently energy is spent for syn-
thesizing proteins and regulating cell death processes,
whereas in resistant cells energy is mainly produced
and utilized in cell growth maintenance. Thus, if this
hypothesis is confirmed by the laboratory approaches,
energy starvation strategies could be used to treat can-
cer cells.
Unexpectedly, categories ‘M’, describing motion of cells,
and ‘V’, denoting the vascularization and angiogenesis, were
found in sensitive cell lines, whereas adhesion-related genes,
‘AD’, were found relatively overexpressed in resistant cell
lines. We have also found that certain categories related to
energy metabolism; marked as ‘M-c’ for metabolism of
carbohydrates and ‘E’ for energy-related processes are also
up regulated in sensitive cells (Additional file 8a).
Although extracellular region ‘EC’ is the top regulated
category in irreversible inhibitor-resistant cell lines,
important EGFR-activated cellular processes, including
immunity, ‘IM’, angiogenesis, ‘V’, and cytoskeleton, ‘CY’,
were upregulated (Additional file 8b). In sensitive cell
lines membrane systems, ‘MM’, response to hormones,
‘R’, and cell cycle, ‘CC’, were upregulated.
In Cetuximab antibody-resistant cell lines, many onto-
logical categories are suppressed. For example, onto-
logical category ‘IM’, immunity, is statistically the mostprominent, biosynthesis of inflammatory cytokine and
responses to these cytokines are specifically downregu-
lated. We have observed that gene ontologies related to
migration of the cells, marked ‘M’, are prominent in
Additional file 8c. Cell adhesion categories, designated
as ‘AD’, are also present there but the enrichment score
and p-values are comparatively less. Blood vessels devel-
opment processes, ‘V’, are overexpressed in Cetuximab-
sensitive cell lines.
We have also found increased expression of signaling,
‘S’, apoptosis inhibition, ‘A’, and homeostasis-related genes,
‘H’, in sensitive cell lines, but not in resistant cell lines.
Some of the overregulated clusters were also related to
cell cycle, ‘CC’, transcription, ‘T’, and responses to external
stimuli, ‘R’. Ectoderm development category was overex-
pressed with higher p-value in antibody-resistant cell
lines, reflecting epidermal cell origin. Other ontological
categories were extracellular matrix ‘EC’ and adhesion
(Additional file 8c).
As observed above, (Tables 3,4,5 and 6), we have seen that
responses of antibody-resistant cell line are rev- erse of those
observed in tyrosine kinase inhibitors-resistant cell lines
(comparing Additional files 8a and b with Table 6c). All
ontological categories observed in Cetuximab-sensitive cell
lines seem responsible for tumor cell survival and progres-
sion and were previously seen overexpressed in tyrosine
kinase inhibitor-resistant cell lines.
Discussion
Global metaanalysis of EGFR inhibitor-resistant vs. sensitive
cell lines presented here identifies the transcriptional and
metabolic differences that allow tumor cells to evade EGFR-
targeted therapies. Specifically, we find that the most acute
problem created by EGFR inhibition is to provide a suffi-
cient energy supply to the proliferating and metabolizing
transformed cells. This metabolic predicament for tumors
was one of the first ones identified, already by Warburg in
1927 [28]. The energy deficit caused by inhibition of EGFR
is overcome by several mechanisms, e.g., by major
enhancement of the mitochondrial oxidative phosphoryl-
ation in Erlotinib-inhibited cells, or by promoting
vascularization and angiogenesis in Gefitinib-inhibited
tumors.
In aerobic glycolysis, tumor cells produce lactate by gly-
colysis in the presence of oxygen and decrease the oxidative
phosphorylation due to presence of an isoform of pyruvate
kinase. If pyruvate kinase is in its native form, then in-
creased oxygen uptake and oxidative phosphorylation occur
and lactate formation is decreased [29]. In metaanalysis of
Erlotinib-resistant cells we found that mitochondrial
processes involving oxidative phosphorylation were upregu-
lated. Moreover, the resistant cells recruit supplementary
energy sources, inducing enzymes that catabolize
carbohydrates in addition to those catabolizing lipids.
Table 6 Comparison of ontological categories differentially expressed in Cetuximab-sensitive vs. resistant cell lines
Cetuximab: Overexpressed in sensitive cells Overexpressed in resistant cells
Term p_value Term p_value
Table 6a
IM response to wounding 1.3E-10 DF ectoderm development 9.2E-10
CC regulation of cell proliferation 1.6E-09 DF epidermis development 1.4E-09
CC positive regulation of cell proliferation 3.5E-07 DF epithelium development 1.0E-08
M chemotaxis 8.9E-07 DF epithelial cell differentiation 1.5E-07
M taxis 8.9E-07 DF keratinocyte differentiation 6.2E-05
M cell migration 1.7E-06 DF cornified envelope 6.5E-05
M localization of cell 2.6E-06 EC extracellular matrix 7.8E-05
M cell motility 2.6E-06 DF epidermal cell differentiation 1.2E-04
M Cell communication 3.5E-06 DF peptide cross-linking 1.7E-04
R regulation of response to external stimulus 4.0E-06 IM wound healing 1.7E-04
Table 6b
IM inflammatory response 6.5E-06 CC regulation of cell proliferation 4.3E-04
IM wound healing 9.1E-06 CY Cell structure and motility 3.3E-04
IM immune response 9.8E-06 CY 12q12-q13 6.9E-04
IM Immunity and defense 6.7E-05 T transcription repressor activity 8.4E-04
IM regulation of inflammatory response 3.5E-04
S Signal transduction 1.5E-05
S Jak-STAT signaling pathway 5.1E-04
S JAK-STAT cascade 6.7E-04
V regulation of vascular endothelial growth factor production 3.2E-05
V Angiogenesis 3.8E-05
V blood coagulation 5.8E-04
a) Top ten categories with best p-values. b) Selected categories with p-value better than 10-4 (see Additional file 7).
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kinase inhibitors-resistant cancer cell lines express specific
inflammatory cytokines and angiogenesis signals to promote
vascularization and perhaps autocrine immunity stimulation
as important strategy to combat cancer treatment [13,30].
In-depth perusal of the processes enhanced in the resistant
cell lines revealed involvement of interleukins and chemo-
kines with C-X-C motif. These observations are in line with
previously known facts that cancer cells use immune cells
and cytokines in various ways to maintain their own prolif-
eration [25]. This mode of overcoming EGFR inhibition is
particularly prominent in cells selected for Gefitinib
resistance.
Perhaps expectedly, while the sensitive cell lines depend
on the ErbB-dependent signaling, resistant ones circum-
vent this pathway and, at least in some cases, rely on the
Ras pathway. Parenthetically, the mutations that confer
EGFR inhibitor resistance generally occur in EGFR,
seldom in Ras. In targeted therapy, as is case of EGFR in-
hibition, small molecules targeting tyrosine kinase domain
of EGFR or monoclonal antibodies specifically blocking
the ligand binding site are used. In some tumors,ErbB-independent signaling is sustained by activation of
downstream molecules, for example Ras, PKI3CA and
BRAF [15,21,31-34]. Correspondingly, we find that in
EGFR inhibitor-resistant cell lines, Ras-dependent onco-
genic pathways are preferentially expressed as a strategy
to overcome the EGFR inhibition (Table 2b). Detailed ana-
lysis of the ErbB and Ras pathway genes enhanced in the
sensitive and resistant cell lines respectively, revealed that
genes involved in these ontological categories are quite
dissimilar (Table 2d).
Interestingly, we found that irreversible inhibitors of the
EGFR signaling pathway increased in resistant cell lines
the expression of multiple EGFR ligands (Table 5b,c). This
seems to be an important alternative to other modes of
overcoming EGFR inhibition [11,35].
Hypoxia stimulates various processes in cancer cells
including vascularization, growth factor signaling, gen-
etic instability, cell survival, metastasis, cell death and
antitumor drug resistance, in general favoring tumor
survival and propagation [36]. The cells in surrounding
areas of low oxygen are considered resistant to antitu-
mor drugs mainly due to non-availability of drug, change
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increase in mutations, angiogenesis and metastasis genes
enhancement [26]. Metaanalysis comparing data from
Gefitinib-sensitive versus resistant cell lines revealed that
gene ontologies responsive to lower oxygen levels are spe-
cifically upregulated in resistant cell lines thus favoring
survival. This finding further supports our observation
that use of different inhibitors results in different, specific
strategies to resist the antitumor targeted therapy.
An important caveat in this analysis stems from the
fact that few of the studies, namely GSE34228 and
GSE38310 for Gefitinib and Erlotinib, respectively, dom-
inate the metaanalysis by overwhelming numbers of mi-
croarrays. Therefore, we cannot claim at this point that
it is the resistance to Gefitinib that specifically produces
the described changes in all cell lines selected for resist-
ance to Gefitinib, and mutatis mutandis, the same for
Erlotinib. However, we note that both GSE34228 and
GSE38310 compared Non-Small Cell Lung Cancer lines,
so the characteristic differences between Gefitinib- vs.
Erlotinib-selected resistance cannot be ascribed to differ-
ent cell types. Additional data are needed to corroborate
or refute inhibitor-specific characteristics of resistant
cells. That said, our previous metaanalysis demonstrated
that different inhibitors, although working by ostensibly
same mechanisms, cause identifiably different transcrip-
tional responses, which allows for inhibitor-specific de-
velopments of resistance as well.Conclusions
This metaanalysis of transcriptional and metabolic dif-
ferences between EGFR inhibitor-resistant vs. sensitive
cell lines identifies changes that allow tumor cells to
evade EGFR-inhibition. The use of different inhibitors
results in different, specific strategies to resist the antitu-
mor therapy. Common pathways are upregulated in cell
lines resistant to inhibitors targeting the kinase domain
of EGFR, however, there are certain processes uniquely
expressed against some of the inhibitors but, apparently,
not others. The development of resistance to antibody
inhibitors can vary significantly.
We found that the most acute problem created by
EGFR inhibition is to provide a sufficient energy supply
to the cells. The energy deficit can be overcome by sev-
eral routes, e.g., by boosting mitochondrial oxidative
phosphorylation, or by promoting vascularization and
angiogenesis.
Further study of sensitive and resistant cancer cell lines
responses to additional EGFR inhibitors will improve our
understanding of drug resistance development and thus
lead to improved anticancer treatment strategies. For ex-
ample, use of mitochondrial blockers with Erlotinib, im-
munity blockers with Gefitinib, or combining tyrosinekinase inhibitors with antibody inhibitors, may avoid de-
velopment of resistance to EGFR inhibitors.
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Additional file 1: Figure S1. Flow chart of metaanalysis procedure.
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